Quote:
Originally Posted by wannabe
New Data Presented At ECTRIMS Congress Show TYSABRIŽ Has Sustained Effect On Relapse Rate In Multiple Sclerosis Patients Treated For Up To Three Years
|
Hmmm...Only 13% (250)of the original 1900 patients remained for the open label extension study. What happened to the other 87%? If you only take the data from these 250 patients, who obviously were doing well on Tysabri, it's not surprising to arrive at those efficacy numbers! Or am I missing something here?
Harry